

Clinical Oversight Review Board (CORB) Criteria for Prescribing Mirikizumab-mrkz IV (Omvoh IV)

Notes:

- Quantity Limits: NO (N/A – IV medication)
- Note: Quantity limits do apply to subcutaneous mirikizumab-mrkz
- ^ Adequate trial is defined as the following:
 - Biologics – 12 weeks
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation
- **Trial of a second TNF-inhibitor is NOT required if the patient experienced primary or secondary treatment failure with the first TNF-inhibitor despite a therapeutic drug level

Non-Formulary **mirikizumab-mrkz (Omvoh)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

Initiation (new start) criteria: Non-formulary **mirikizumab-mrkz IV (Omvoh IV)** will be covered under the medical benefit for 3 doses when the following criteria are met:

1. Patient has a diagnosis of moderate to severe Crohn's disease
 - Prescriber is a gastroenterologist
 - Patient is 18 years of age or older
 - Patient has failed an adequate trial of, has an allergy or intolerance* to, or has a contraindication to the following:
 - At least 2 tumor necrosis factor (TNF)-inhibitors**
 - Infliximab product
 - Adalimumab product (criteria based)
 - Certolizumab (criteria based)
 - Ustekinumab product (criteria based)
 - Risankizumab-rzaa (criteria based)
2. Patient has a diagnosis of moderate to severe ulcerative colitis
 - Prescriber is a gastroenterologist
 - Patient is 18 years of age and older
 - Patient has failed an adequate trial of, has an allergy or intolerance* to, or has a contraindication to the following:
 - Infliximab product
 - Ustekinumab product (criteria based)
 - Tofacitinib (criteria based) or upadacitinib (criteria based)
 - Guselkumab (criteria based)
 - Risankizumab-rzaa (criteria based)

kp.org

Revised: 04/10/25
Effective: 06/19/25

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest